Hypopigmentation, Organomegaly, and Delayed Myelination and Development

1. Disease Information

• Overview: HOD ("Hypopigmentation, Organomegaly, and Delayed Myelination and Development") is a multisystem congenital disorder combining diffuse skin/hair/eye hypopigmentation (albinism-like), organomegaly (hepatosplenomegaly), and neurodevelopmental impairment with delayed CNS myelination. It is a lysosomal storage phenotype driven by abnormal lysosomal acidification.
• Key identifiers:
• OMIM #618541 — "Hypopigmentation, Organomegaly, and Delayed Myelination and Development."
• Gene: CLCN7 (OMIM *602727), HGNC:2023, locus 16p13.3.
• Mondo: MONDO:0032781 (HOD; per Mondo cross-reference to OMIM 618541 — to be confirmed against current Mondo release).
• Orphanet / ICD-11: No dedicated Orphanet code identified; closest ICD-11 grouping is under lysosomal/metabolic and pigmentary disorders. ICD-10: no specific code (would map broadly to E75.- lysosomal / E70.3 albinism categories). Not available as a discrete code.
• MeSH: No dedicated MeSH descriptor; relevant terms: "Lysosomal Storage Diseases", "Albinism", "CLCN7 protein, human".
• Synonyms / alternative names: "CLCN7-related gain-of-function lysosomal disorder"; "CLCN7 gain-of-function hypopigmentation and lysosomal storage disease"; informally "HOD syndrome." Related descriptor in literature: "multisystem disorder associated with a pathogenic variant in CLCN7 in the absence of osteopetrosis."
• Data source: Information is individual-patient / small-case-series derived (fewer than ~10 reported probands), supported by disease-level functional/model-organism resources. This is not an aggregated EHR-scale entity.

2. Etiology

• Primary cause (genetic): Heterozygous de novo gain-of-function (GoF) missense variants in CLCN7. Index variant p.Tyr715Cys (Y715C) in the C-terminal cystathionine-β-synthase (CBS) domain; the original AJHG report (Nicoli et al., 2019; PMID 31155284) described additional de novo variants (e.g., p.Tyr99Cys/Y99C in the transmembrane domain) with the same functional signature. Functional testing shows increased outward currents → lysosomal hyperacidity (PMID 39056574, 31155284).
• Genetic risk factors: The causal variants are the sole known determinant; because they are de novo and dominant-acting, there is no meaningful susceptibility-locus/modifier background documented. Modifier genes and compensatory pathways are hypothesized but unproven (PMID 39056574).
• Environmental risk factors: None identified. This is a monogenic disorder; onset is congenital and independent of exposures, lifestyle, or sex.
• Protective factors: None described. (Hypothetically, lowering ClC-7 activity/lysosomal acidity could be protective — see Treatment.)
• Gene–environment interactions: Not applicable / none reported.

3. Phenotypes

All frequencies are qualitative given the very small case count (individual-patient evidence).

• Progression: Neurodevelopmental features are static-to-slowly-progressive; underlying storage biology in models is progressive/neurodegenerative.
• Quality-of-life impact: Substantial — visual impairment (albinism, nystagmus), developmental disability, and immune susceptibility affect daily function. No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare entity.
• Notably ABSENT: osteopetrosis/increased bone density (distinguishes HOD from CLCN7 LoF disease).

4. Genetic / Molecular Information

• Causal gene: CLCN7 (HGNC:2023; NCBI Gene 1186; UniProt P51798, CLCN7_HUMAN), 16p13.3. Encodes ClC-7, a voltage-gated CLC-family Cl⁻/H⁺ antiporter (2Cl⁻:1H⁺ stoichiometry).
• Pathogenic variants (HOD, GoF):
• c.296A>G, p.Tyr99Cys (Y99C) — transmembrane domain (original de novo cases, Nicoli 2019).
• c.2144A>G, p.Tyr715Cys (Y715C) — C-terminal CBS domain (Nicoli 2019; Lee 2024, PMID 39056574).
• Variant type/class: missense (single amino-acid substitutions); germline de novo, not somatic.
• Classification (ACMG/AMP): pathogenic/likely pathogenic (de novo, functionally validated, absent from population databases).
• Allele frequency: Absent from gnomAD (private de novo). CLCN7 is highly constrained.
• Functional consequence: Gain of function — increased Cl⁻/H⁺ transport → lysosomal hyperacidification and accelerated/enhanced currents (PMID 39056574, 31155284, 38136669).
• Contrast — CLCN7 osteopetrosis variants: Dominant-negative (ADO2/Albers-Schönberg, e.g., p.Gly213Arg) or biallelic loss-of-function/NMD (ARO, e.g., p.Met59Asnfs*8) — opposite functional direction, different disease (PMID 11741829, 39994654, 17936098).
• Modifier genes: OSTM1 (obligate β-subunit) is essential for ClC-7 function; unproven as a HOD modifier. Others hypothesized (PMID 39056574).
• Epigenetic / chromosomal abnormalities: None reported; disease is single-nucleotide/missense, not structural.

Ontology suggestions: Gene HGNC:2023 (CLCN7); protein UniProt P51798; partner OSTM1 (HGNC:16800, UniProt Q86WC4).

5. Environmental Information

• Environmental factors: None. Congenital monogenic disorder.
• Lifestyle factors: Not applicable.
• Infectious agents: None causal. (Note: hypogammaglobulinemia may predispose to recurrent infections as a consequence, not a cause.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. A de novo gain-of-function missense variant in CLCN7 (e.g., Y99C, Y715C) alters ClC-7 gating/coupling → leads to increased 2Cl⁻/1H⁺ antiporter activity (demonstrated by increased outward currents in Xenopus oocytes; PMID 39056574, 31155284).
2. Enhanced Cl⁻ counter-ion flux provides greater charge shunt for the V-ATPase → results in over-acidification (hyperacidity) of lysosomes and lysosome-related organelles (demonstrated: "lysosomal hyperacidity"; PMID 39056574).
3. Abnormally low luminal pH disrupts pH-optimal lysosomal hydrolases and membrane trafficking → impairs autophagic/degradative clearance (demonstrated in cell models of GoF variants; PMID 38136669) → results in accumulation of undigested storage material and cytoplasmic vacuolization (demonstrated; PMID 39056574).
4. Branch A — Melanosomes (pigment): melanosomes are lysosome-related organelles whose melanin synthesis (tyrosinase) is exquisitely pH-sensitive. Hyperacidification impairs melanin production → generalized hypopigmentation / albinism-like phenotype (inferred mechanism, supported by melanosome-pH biology and the albinism phenotype in Nicoli 2019 / Polovitskaya 2024).
5. Branch B — Reticuloendothelial storage: storage-material accumulation in hepatic/splenic macrophages and parenchyma → hepatosplenomegaly / organomegaly (inferred from lysosomal-storage biology; consistent with organomegaly in reported patients).
6. Branch C — CNS: neuronal and glial (oligodendrocyte, microglial) storage and dysfunction → impaired myelination and neuronal function → delayed myelination + developmental delay (supported by Clcn7-KO mouse neurodegeneration/NCL-like storage, PMID 15706348, and microglial phagocytic failure, PMID 38294065).
7. Branch D — Immune: impaired lysosomal/endosomal processing in B-lineage/antigen-processing cells → hypogammaglobulinemia (reported; PMID 39056574).
8. Chronic storage/vacuolization in neurons and glia is inferred to drive progressive neurodegeneration (from model organisms; NCL-like subunit-c and lysosomal-enzyme accumulation, PMID 15706348).

Category detail

• Molecular pathways: Lysosomal ion homeostasis / V-ATPase-coupled acidification; autophagy–lysosome pathway; mTORC1 lysosomal signaling (inferred). Reactome "Ion channel transport"; KEGG "Lysosome" (map04142).
• Cellular processes: Autophagic clearance (impaired), lysosomal degradation, phagocytosis (microglial clearance of apoptotic cells/β-amyloid impaired; PMID 38294065), melanogenesis.
• Protein dysfunction: ClC-7 GoF (altered gating/uncoupling of Cl⁻/H⁺ transport); obligate complex with OSTM1 — OSTM1 is required for ClC-7 stability (ClC-7 protein falls >90% in Ostm1-null grey-lethal mice; PMID 16525474) and the OSTM1 dimer shields luminal ClC-7 (cryo-EM; PMID 32749217).
• Disease-family paradigm: HOD belongs to a broader class of endolysosomal CLC gain-of-function neurodevelopmental disorders — a recurrent GoF mutation in the paralog CLCN6 (ClC-6) causes a neurodevelopmental/neurodegenerative disorder via the same endolysosomal-ion-homeostasis logic (Polovitskaya et al. 2020, PMID 33217309), and endolysosomal CLC dysfunction generally produces NCL-like storage and neurodegeneration (review PMID 33708769; CLC-3 deficiency NCL model PMID 12059962).
• Metabolic changes: Accumulation of NCL-type storage (subunit c of mitochondrial ATP synthase) and lysosomal enzymes (PMID 15706348).
• Immune involvement: Hypogammaglobulinemia; microglial dysfunction.
• Tissue-damage mechanism: Storage-driven cellular dysfunction and neurodegeneration (astrogliosis, microglial activation in models).
• Biochemical abnormality: Dysregulated lysosomal pH set-point (hyper-acidic).

Melanosome-pH sub-mechanism (hypopigmentation branch, supporting evidence): Melanosomal luminal pH is a master regulator of melanin synthesis; tyrosinase (the rate-limiting melanogenic enzyme) is minimally active in an acidic environment (Miao et al. 2019, PMID 31214276), and melanosomal pH is normally set by V-ATPase proton pumping balanced by ion transporters (SLC45A2/OCA4, OCA2 P-protein, SLC24A4/5) (Cheli et al. 2009, PMID 19389708). ClC-7 supplies the Cl⁻ counterion that enables V-ATPase-driven organelle acidification (Mindell 2012, PMID 22335796). Thus ClC-7 GoF → melanosome over-acidification → tyrosinase suppression → hypopigmentation. This places HOD within a broader class of "ion-transport / organelle-pH" albinism syndromes — e.g., gain-of-function TPC2 p.R210C albinism (PMID 36641477) and V-ATPase-deficiency oculocutaneous albinism in zebrafish (PMID 18836173).

GO/CL suggestions: GO:0007042 (lysosomal lumen acidification), GO:0055085 (transmembrane transport), GO:1902600 (proton transmembrane transport), GO:0006914 (autophagy), GO:0006622 (protein targeting to lysosome), GO:0006583 (melanin biosynthetic process from tyrosine), GO:0042470 (melanosome). Cellular component: GO:0005765 (lysosomal membrane), GO:0042470 (melanosome). Cell types: CL:0000540 (neuron), CL:0000128 (oligodendrocyte), CL:0000129 (microglial cell), CL:0000148 (melanocyte), CL:0000091 (Kupffer cell), CL:0000236 (B cell).

CHEBI suggestions: CHEBI:17594 (melanin), CHEBI:17996 (chloride), CHEBI:24636 (proton/H⁺), CHEBI:15377 (water), CHEBI:18059 (lipid, storage material context). Key protein/enzyme: tyrosinase (EC 1.14.18.1, UniProt P14679).

7. Anatomical Structures Affected

• Organ level: Skin & hair (pigment), eyes (iris/retina), liver & spleen (organomegaly), central nervous system (white matter/brain), immune system (B-cell compartment). Bone is spared (no osteopetrosis).
• Body systems: Integumentary, nervous, hepatobiliary/reticuloendothelial, visual/ophthalmic, immune.
• Tissue/cell level: Melanocytes (CL:0000148); neurons (CL:0000540) and oligodendrocytes (CL:0000128, myelination); microglia (CL:0000129); Kupffer cells/macrophages (CL:0000235/CL:0000091); B lymphocytes (CL:0000236).
• Subcellular: Lysosome (GO:0005764) and lysosomal membrane (GO:0005765); lysosome-related organelles / melanosomes (GO:0042470); late endosome (GO:0005770); autophagosome (GO:0005776).
• Localization / lateralization: Systemic and bilateral/symmetric (pigmentary, hepatosplenic, CNS white-matter changes are generalized).

UBERON suggestions: UBERON:0002097 (skin of body), UBERON:0002107 (liver), UBERON:0002106 (spleen), UBERON:0000955 (brain), UBERON:0002316 (white matter), UBERON:0000970 (eye).

8. Temporal Development

• Onset: Congenital / neonatal (hypopigmentation evident at birth; developmental delay and organomegaly in infancy).
• Onset pattern: Chronic, insidious.
• Progression: Neurodevelopmental delay is largely static-to-slowly-progressive in reported patients; model-organism data indicate an underlying progressive neurodegenerative storage process.
• Course: Chronic, lifelong. No remission described.
• Critical periods: Early infancy (myelination window) is the key period of CNS vulnerability and the plausible window for intervention.

9. Inheritance and Population

• Epidemiology: Ultra-rare; <10 reported cases worldwide (individual case reports/small series). Prevalence/incidence not estimable (effectively unknown; well below 1/1,000,000).
• Inheritance: Autosomal dominant, de novo (sporadic). Not inherited from parents in reported cases.
• Penetrance: Presumed complete for the specific GoF alleles (all reported carriers affected).
• Expressivity: Variable (developmental severity, immune involvement differ between patients).
• Anticipation / mosaicism / founder effects / consanguinity / carrier frequency: Not applicable (de novo dominant; no carrier state, no founder or consanguinity role). Germline mosaicism is theoretically possible for recurrence risk counseling but unreported.
• Population demographics: No ethnic predilection; cases reported across populations (e.g., a Taiwanese proband, PMID 39056574). No sex bias expected (autosomal). Age distribution: pediatric.

10. Diagnostics

• Genetic testing (definitive):
• Trio whole-exome (WES) or whole-genome (WGS) sequencing to detect the de novo CLCN7 missense variant (approach used in all reported cases). Single-gene CLCN7 sequencing or lysosomal/leukodystrophy gene panels including CLCN7 are alternatives.
• Functional confirmation: electrophysiology (Xenopus oocyte currents) demonstrating GoF; lysosomal pH measurement showing hyperacidity (research setting).
• CMA/karyotype/FISH/mtDNA/repeat testing: not indicated (point-mutation disease).
• Clinical/laboratory:
• Ophthalmologic exam (iris transillumination, nystagmus, foveal hypoplasia, VEP) for albinism.
• Abdominal ultrasound/MRI for hepatosplenomegaly.
• Brain MRI: delayed/deficient myelination, white-matter signal changes.
• CBC/blood smear: vacuolated lymphocytes; immunoglobulin panel (hypogammaglobulinemia).
• Skin/marrow biopsy or EM: lysosomal storage material/vacuolization (research/confirmatory).
• Differential diagnosis: Oculocutaneous albinism (OCA1–7; distinguished by absence of organomegaly/CNS storage), Chediak-Higashi & Hermansky-Pudlak syndromes (lysosome-related organelle disorders with pigment dilution — distinguished by giant granules/bleeding/immune profile and their own genes), other lysosomal storage/leukodystrophies, CLCN7 osteopetrosis (distinguished by increased bone density — absent in HOD).

LOINC/ontology suggestions: genetic sequencing panels; brain MRI (RadLex).

11. Outcome / Prognosis

• Survival/mortality: No formal survival statistics (too few cases). Reported patients have survived into childhood; long-term prognosis is guarded owing to neurodevelopmental disability and potential progressive neurodegeneration (extrapolated from ClC-7-deficiency models).
• Morbidity/function: Significant lifelong disability — visual impairment, developmental/intellectual disability, and infection susceptibility (hypogammaglobulinemia).
• Complications: Recurrent infections (immune), visual complications of albinism, feeding/growth issues.
• Prognostic factors: Severity of developmental delay and extent of CNS myelination deficit; degree of immune involvement.
• Prognostic biomarkers: None validated; lysosomal storage burden and MRI myelination are candidate markers.

12. Treatment

No disease-specific or curative therapy exists; management is supportive.

• Supportive/rehabilitative (mainstay): Developmental/early-intervention therapy, physical/occupational/speech therapy (NCIT: rehabilitation therapy); low-vision aids and ophthalmologic management for albinism; photoprotection (sun protection, given hypopigmentation → skin-cancer risk).
• Immune: Immunoglobulin replacement (IVIG) and infection prophylaxis if clinically significant hypogammaglobulinemia (NCIT: Intravenous Immunoglobulin Therapy).
• Organomegaly/storage: Monitoring; no approved substrate-reduction/enzyme therapy for this entity.
• Pharmacogenomics: None established.
• Mechanism-rational (experimental/hypothetical): Because the defect is lysosomal hyper-acidification from ClC-7 GoF, agents that raise lysosomal pH / reduce ClC-7 or V-ATPase activity are conceptually attractive but untested in patients. ClC-7 inhibitors are in preclinical study for other indications. No gene-, cell-, or RNA-based therapy has been reported for HOD.
• Advanced therapeutics (osteopetrosis contrast): Hematopoietic stem-cell/bone-marrow transplant is standard for recessive osteopetrosis and studied for ADO2 in mice (PMID 35959867) — not applicable to HOD, which lacks the osteoclast/bone phenotype.
• Clinical trials: None specific to HOD identified on ClinicalTrials.gov (no NCT).

13. Prevention

• Primary prevention: Not possible (de novo mutation); no modifiable risk factors.
• Secondary prevention: Early diagnosis via trio sequencing enables early developmental intervention, vision support, and immune monitoring.
• Genetic counseling: Recurrence risk for parents is low (de novo), but germline mosaicism cannot be excluded → prenatal/preimplantation testing can be offered for known familial variants. Affected individuals would have 50% transmission risk (autosomal dominant), though reproduction is unlikely given severity.
• Screening: Not part of newborn/carrier screening panels. Cascade testing not generally indicated for de novo cases.
• Public-health/immunization/prophylaxis: Standard vaccination and infection prophylaxis if immunodeficient.

14. Other Species / Natural Disease

• Taxonomy / orthologs: CLCN7 is highly conserved. Orthologs: mouse Clcn7 (NCBI Gene 26373; NCBI Taxon 10090), rat Clcn7, zebrafish clcn7 (Taxon 7955). Partner Ostm1 similarly conserved.
• Natural disease in animals: Naturally occurring CLCN7/OSTM1 loss-of-function osteopetrosis exists (e.g., the mouse grey-lethal (gl, Ostm1) and Clcn7 mutants; cattle/dog osteopetrosis — OMIA entries for CLCN7-related osteopetrosis). No naturally occurring gain-of-function HOD counterpart is documented in animals.
• Comparative biology: Loss of ClC-7/Ostm1 recapitulates lysosomal storage + neurodegeneration + osteopetrosis across species, confirming conserved lysosomal/osteoclast roles; the grey-lethal mouse also shows coat-color/pigment dilution, echoing the pigment link.
• Zoonotic potential: None (genetic disease).

15. Model Organisms

• Mouse (primary):
• Clcn7⁻/⁻ knockout — severe lysosomal storage disease + neurodegeneration (NCL-like, subunit-c and lysosomal-enzyme accumulation), retinal degeneration, osteopetrosis; osteoclast-rescue transgene extends life but CNS disease progresses (PMID 15706348). Recapitulates the storage/neurodegeneration axis of HOD (but represents LoF, so bone phenotype opposite).
• Ostm1 (grey-lethal) mutant — phenocopy of Clcn7 loss (lysosomal storage, neurodegeneration, osteopetrosis, coat-color dilution).
• ADO2 knock-in (p.G213R) — dominant-negative bone model (PMID 35959867) — informs CLCN7 dominant biology though not the GoF HOD mechanism.
• Knock-in of HOD GoF alleles (e.g., Y99C/Y715C) — appropriate model to recapitulate hyperacidification/hypopigmentation; described in the 2024 GoF characterization work (Polovitskaya et al., PMID 38838776).
• Zebrafish: clcn7 and ostm1 mutants show microglial/macrophage phagocytic failure (impaired clearance of apoptotic cells and β-amyloid) with normal microglial development (PMID 38294065) — models the neuroimmune/clearance component.
• In vitro/heterologous: Xenopus oocyte and mammalian-cell expression for electrophysiology and lysosomal-pH assays (functional variant validation; PMID 31155284, 38136669, 33125761); Arabidopsis vacuole system for CLC-7 transport mechanism (PMID 22641774).
• Model limitations: Mouse KO models loss-of-function, not the human GoF; GoF knock-ins and patient iPSC-derived neurons/melanocytes are needed to fully model HOD-specific hyperacidification and hypopigmentation.
• Resources: MGI (Clcn7, Ostm1), ZFIN (clcn7), IMPC/IMSR for alleles; OMIA for animal osteopetrosis.

Key References (PMID)

• 31155284 — Nicoli et al. 2019, Am J Hum Genet. Original description: de novo CLCN7 variant → lysosomal storage + albinism via altered lysosomal acidification (the defining HOD paper).
• 38838776 — Polovitskaya et al. 2024. Gain-of-function CLCN7 variants cause hypopigmentation and lysosomal storage disease (mechanistic/model confirmation).
• 39056574 — Lee et al. 2024. Multisystem CLCN7 p.Y715C disorder (developmental delay, organomegaly, hypogammaglobulinemia, hypopigmentation) without osteopetrosis; GoF/lysosomal hyperacidity.
• 38136669 — Bose et al. 2023. Impaired autophagic clearance with a GoF ClC-7 variant.
• 32749217 — Schrecker et al. 2020. Cryo-EM of CLC-7/OSTM1 complex.
• 15706348 — Kasper et al. 2005. Clcn7-KO mouse: lysosomal storage disease + neurodegeneration.
• 38294065 — Iyer & Talbot 2024. ClC-7 essential for microglial phagocytic clearance (zebrafish).
• 33125761 — Di Zanni et al. 2021. Structure/function of 14 ClC-7 mutants; lysosomal localization ↔ neurodegeneration.
• 11741829 — Cleiren et al. 2001. ADO2 = dominant-negative CLCN7 (contrast to GoF HOD).
• 17936098 — Del Fattore et al. 2008. Osteopetrosis genetics/pathogenesis review.
• 35959867 — Alam et al. 2022. BMT for ADO2 in mice.
• 11207362 — Kornak et al. 2001. ClC-7-deficient mice: osteopetrosis + retinal degeneration; ClC-7 provides Cl⁻ conductance for osteoclast H⁺-ATPase.
• 16525474 — Lange et al. 2006. ClC-7 requires OSTM1 β-subunit; grey-lethal (Ostm1-null) mice phenocopy Clcn7-null (storage, neurodegeneration, osteopetrosis).
• 33217309 — Polovitskaya et al. 2020. Recurrent gain-of-function CLCN6 (ClC-6) mutation → neurodevelopmental/neurodegenerative disorder (endolysosomal CLC GoF paradigm).
• 33708769 — Bose, He & Stauber 2021. Review: neurodegeneration upon dysfunction of endosomal/lysosomal CLC transporters.
• 12059962 — Yoshikawa et al. 2002. CLC-3 deficiency → NCL-like phenotype with subunit-c accumulation and elevated endosomal pH.
• 22335796 — Mindell 2012. Lysosomal acidification mechanisms (V-ATPase + ClC-7 counterion).
• 31214276 — Miao et al. 2019. Intramelanocytic acidification suppresses tyrosinase/melanogenesis.
• 19389708 — Cheli et al. 2009. Melanosome pH as key regulator of melanin synthesis (αMSH/cAMP).

Consolidated Causal-Chain Synthesis (knowledge-base ready)

One defect, four tissue readouts. A de novo gain-of-function CLCN7 missense variant → increased ClC-7 2Cl⁻/1H⁺ antiporter activity → excess counterion shunt for the V-ATPase → over-acidification of lysosomes and lysosome-related organelles → branches: - Melanosome branch → tyrosinase (pH-sensitive, minimal activity when acidic) suppressed → reduced melanin → hypopigmentation / albinism (HP:0001010; evidence: in vitro melanosome-pH biology + human). - Autophagy/visceral branch → hydrolase pH-mismatch → impaired autophagic/lysosomal clearance → storage material + vacuolization in liver/spleen macrophages → organomegaly (HP:0003271; evidence: human cells + in vitro). - Neural branch → neuronal/oligodendrocyte/microglial lysosomal dysfunction and NCL-like storage → delayed myelination + developmental delay (HP:0012448, HP:0001263; evidence: model organism + human). - Immune branch → impaired endolysosomal processing in B-lineage cells → hypogammaglobulinemia (HP:0004313; evidence: human case). - Spared: osteoclast bone resorption (requires reduced ClC-7) → no osteopetrosis (the discriminating negative feature).

Confirmed Findings Recorded (6)

1. HOD (OMIM 618541) = de novo gain-of-function CLCN7 — mirror image of loss-of-function/dominant-negative osteopetrosis [human + in vitro; PMID 39056574, 31155284, 11741829].
2. ClC-7/OSTM1 dysfunction → lysosomal storage + NCL-like neurodegeneration; obligate OSTM1 complex [model organism + structural; PMID 15706348, 32749217, 16525474, 33125761].
3. Clinical triad hypopigmentation + organomegaly + delayed myelination/development without osteopetrosis [human; PMID 39056574].
4. Hypopigmentation via melanosome over-acidification suppressing tyrosinase [in vitro/human; PMID 31214276, 19389708, 22335796].
5. Organomegaly via impaired autophagic clearance and reticuloendothelial storage [in vitro/human; PMID 38136669, 39056574].
6. Delayed myelination/development via neural + microglial lysosomal failure; endolysosomal-CLC GoF paradigm (CLCN6) [model organism + human; PMID 16525474, 11207362, 38294065, 33217309, 33708769].

Evidence-Source Classification

• Human clinical: PMID 31155284 (Nicoli 2019, original probands), 39056574 (Lee 2024), 11741829 (osteopetrosis genotype-phenotype).
• Model organism: PMID 15706348 & 11207362 (mouse Clcn7-KO), 16525474 (Ostm1 grey-lethal mouse), 38294065 (zebrafish clcn7/ostm1), 35959867 (ADO2 mouse).
• In vitro / functional / structural: PMID 38136669 (autophagy), 33125761 (14 mutants), 32749217 (cryo-EM), 22335796/31214276/19389708 (pH/melanosome biology), 36641477 (TPC2 albinism), 18836173 (v-ATPase zebrafish).
• Review/computational: PMID 33708769, 17936098, 35159175.

Limitations

• Evidence base is very small (individual case reports + functional/model studies); frequencies, prognosis, survival, and QoL metrics are qualitative.
• Some mechanistic links (melanosome hyperacidification → hypopigmentation; storage → organomegaly; progressive neurodegeneration) are inferred from lysosome/melanosome biology and LoF models rather than directly demonstrated in HOD patients.
• No approved therapy; mechanism-based treatments remain hypothetical.
• Ontology cross-references (Mondo, ICD-11, Orphanet) should be verified against current releases.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:31214276 (2 mentions) - Intramelanocytic Acidification Plays a Role in the Antimelanogenic and Antioxidative Properties of Vitamin C and Its Derivatives.
• shared terms: melanosome

Weighed against this report's own most characteristic terms: lysosomal, storage, clcn7, hypopigmentation, organomegaly, osteopetrosis, hod, myelination, clc-7, albinism, model, gof, novo, variant, developmental, immune, delayed, melanosome, gain-of-function, ostm1.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.